The Global Cancer Landscape: From First- to Third-Generation Targeted Drugs — How Medicine Is Changing the Fate of CancerNot long ago, a cancer diagnosis was almost a death senten...

Treatment of type 1 diabetes (T1D) is entering a transformative era. The first immunotherapy approved to delay clinical onset—Teplizumab—has received FDA approval in the United S...

Many patients say: 'After taking targeted therapy, my tumor shrank, and I feel better. Does this mean I’m cured?' This is a common misconception.Targeted Therapy: Control, Not Com...

Pharmacil is a key pharmaceutical company under the Radiant Group in Bangladesh. Established in 2005 and headquartered in Dhaka, Bangladesh, it boasts modern pharmaceutical prod...

Breast cancer remains the most commonly diagnosed cancer among women worldwide. Although its发病 trends and risk factors have been extensively studied, public understanding of how ...

ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...

Why Cancer Patients Should Eat Less Sugar: The Hidden Link Between Sugar and Tumor GrowthMany cancer patients are told by doctors to “avoid sugar.” But why?Sugar is not poison—b...

Obesity has become a major global public health challenge. According to the World Obesity Federation, approximately 3 billion people worldwide were overweight or obese by 2024. Exc...

Eltromin (Eltrombopag) – Mechanism of Action and Therapeutic IndicationsEltromin, whose generic name is eltrombopag, is an oral thrombopoietin‑receptor agonist (TPO‑RA) widely...

The U.S. Food and Drug Administration (FDA) has officially approved Novartis’ latest gene replacement therapy, Itvisma, marking a significant milestone in the treatment landscape ...